Myonex to Acquire Creapharm’s Clinical & Commercial Packaging and Bioservices Business
Myonex, a leading global clinical trial supply company, has reached an agreement with the owners of Creapharm Group to acquire the Creapharm Clinical Packaging & Distribution and Commercial Packaging business and bioservices, headquartered in Reims, France with additional locations in Bordeaux and Bailly-Romainvilliers, France, and Marietta, Georgia, USA.
The completion of this transaction is subject to regulatory approvals.
This strategic acquisition will bring complementary strengths to the marketplace. Myonex is the market leader in drug sourcing and clinical trial prescription services with growing franchises in clinical packaging, labeling and distribution, and ancillary equipment and supply. Creapharm will bring scale and deep expertise in clinical packaging and distribution alongside existing franchises in commercial packaging and advanced therapy medicinal products (ATMPs) supply chain management.
“By combining, we will fill a gap in the market with broad and deep expertise, integrated services, and extraordinary client focus,” said James Lovett, CEO of Myonex. “Myonex looks forward to combining with our Creapharm colleagues to meet the needs of our clients with agility and speed.”
“Growing with Myonex is an obvious step for Creapharm to move forward, contributing our expertise and wide range of packaging solutions to their operations while we will expand the range of services we offer in support of always more effective, efficient, patient-centric clinical trials,” said Eric Placet, Creapharm’s CEO and Founder. “Creapharm is pleased to evolve the overall mission of Myonex through our complementary strengths and to provide scale and flexibility in meeting our clients’ needs.”
“We have complementary strengths and cultural alignment that make this an exciting solution for the industry, our colleagues and clients,” said Michael Cohen, Myonex’s Co-Owner, and Executive Chairman. “We share traditions of entrepreneurship and engagement with team members, as well as a commitment to social and environmental responsibility to ensure the success of our clients, clinical trial sites and patients.”
Conditional upon the successful completion of the transaction, Mike Cohen will continue as Executive Chairman and James Lovett as CEO of the combined company. Eric Placet will reinvest into Myonex as well as join Myonex’s Board of Directors further solidifying the relationship. Creapharm’s Carla Da Costa will join the combined management teams and Edouard Placet will also have a strategic and leadership role in the combined company.
About Myonex
Myonex is a leading global clinical trial supply company offering tailored solutions in drug sourcing, packaging & labeling, equipment & supplies, and market leading CTRx solution for each trial’s specific requirements and complexities. With our locations in the US, EU, and UK we partner with pharmaceutical and biotechnology companies, contract research organizations (CROs), and other clinical trial service providers seeking a flexible, comprehensive solution for their trial supply needs. Learn more at www.myonex.com.
About Creapharm
With decades of experience in global clinical trial supply management, Creapharm supports Pharma and Biotech key players with customized solutions. Creapharm has a strong expertise in cold-chain management and recently developed ultra-cold solutions to handle biologicals and ATMP supply chain management. For marketed health products, Creapharm offers expert commercial packaging services to pharmaceutical and food supplement industries. Learn more at www.creapharm-pharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240315996717/en/
Contact information
Maryanne Walsh
+1 267-307-0876
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Equazen ® Reaffirms Its Commitment to Uncompromising Quality and Sustainability in Omegas Supplements26.6.2025 09:00:00 EEST | Press release
SFI Health™EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, highlights today its ongoing commitment to delivering the highest standard of quality for Equazen®, the company’s global science-based food supplement brand designed to nourish, enhance and support the brain’s potential. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625554235/en/ Equazen® continues to set the benchmark for excellence at every step of the value chain At SFI Health™, quality is more than a requirement—it is a mission. The company is committed to enhancing people’s well-being by developing natural supplements that combine passion for nature-based healthcare, science, state-of-the-art production standards and sustainability, from ingredient sourcing to the final product reaching the patient. In particular, with over 25 years of trust built across multiple markets, Equazen®'s excellence is built on five core pillars: I
Toyota Kirloskar Motor and Ohmium Collaborate on Potential Opportunities to Develop Green Hydrogen Solutions in India26.6.2025 09:00:00 EEST | Press release
Ohmium International, a leading provider of Proton Exchange Membrane (PEM) hydrogen technology, has signed a Memorandum of Understanding with Toyota Kirloskar Motor Private Limited (India) in New Delhi. The parties will collaborate on the development of hydrogen-based solutions by integrating Toyota’s PEM* fuel cell modules and Ohmium cutting-edge PEM electrolyzers. The event was graced by central and local government. The chief guest who presided was the Hon’ble Union Cabinet Minister Shri Nitin Gadkari, Minister of Roads, Transportation, and Highways along with the guests of honor, Shri Shripad Yesso Naik, Hon’ble Minister of State for New & Renewable Energy, Govt. of India, and Shri Manjinder Singh Sirsa, Hon'ble Minister of Environment, Industries, Food & Supplies and Forest & Wildlife, Govt. of NCT of Delhi. Additionally, Ms. Manasi Tata Kirloskar, Vice Chairperson of Toyota Kirloskar Motor, and Mr. Swapnesh R. Maru, Deputy Managing Director for Corporate Planning and the Green Fi
Murata Pushes Capacitor Design with World’s First 10µF/50Vdc MLCC in 0805-inch Size for Automotive Applications26.6.2025 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced the new GCM21BE71H106KE02 multilayer ceramic capacitor (MLCC) has entered mass production. The device is the world's first 0805-inch size (2.0 x 1.25 mm) MLCC to offer a capacitance of 10µF with a 50Vdc rating and is specifically engineered for automotive applications*. This cutting-edge product marks a significant advancement in MLCC design, delivering a smaller 0805-inch package while maintaining capacitance, voltage rating, and MLCC reliability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250611043543/en/ [Murata Manufacturing Co., Ltd.] 10µF/50Vdc MLCC in 0805-inch Size for Automotive Applications Advancements in advanced driver-assistance systems (ADAS) and autonomous driving (AD) technologies necessitate deploying an increased number of integrated circuits (ICs) within vehicle systems. This surge in ICs simultaneously leads to a greater
Mars’ Pending Acquisition of Kellanova Clears FTC Antitrust Review26.6.2025 03:07:00 EEST | Press release
Mars, Incorporated, a family-owned, global leader in pet care, snacking and food, and Kellanova (NYSE: K), a leader in global snacking, international cereal and noodles and North America frozen foods, today announced that the U.S. Federal Trade Commission (FTC) has concluded its antitrust review of Mars’ pending acquisition of Kellanova. Poul Weihrauch,CEO & Office of the President, Mars, Incorporated, said: “We are very pleased that the FTC has completed its review of the transaction without the imposition of any condition or requiring any remedy. The transaction has now received all but one of the 28 required regulatory clearances, with only the review by the European Commission outstanding. This brings us one step closer to uniting two iconic businesses with complementary footprints and portfolios, allowing us to deliver more choice and innovation to consumers.” Steve Cahillane, Chairman, President & CEO, Kellanova, said: “This represents a significant milestone on our path to combi
VeriSilicon Expands DSP Portfolio with Silicon-Proven ZSP5000 Vision Core Series for Edge Intelligence26.6.2025 03:00:00 EEST | Press release
VeriSilicon (688521.SH) today released the ZSP5000 Digital Signal Processing (DSP) series IPs, which are based on its fifth-generation silicon-proven DSP architecture. This product line adopts a highly scalable and energy-efficient design, and has been deeply optimized for compute-intensive workloads such as computer vision and embedded AI. Combined with the configurable nature of the architecture, this series of IP can provide excellent solutions with both energy and computing efficiency for various edge devices. The ZSP5000 series IPs include ZSP5000, ZSP5000UL, ZSP5000L, and ZSP5000H, delivering scalable vector processing performance ranging from 32 to 256 8-bit Multiply-Accumulate (MAC) operations per cycle. For even higher performance, VeriSilicon’s multi-core ZSP5400H can combine multiple ZSP5000H cores in a multi-cluster architecture to further scale computing capability. The ZSP5000 series features a rich and intuitive instruction set optimized for ease of programming and effic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom